Foundation Medicine and WuXi PharmaTech Collaborate
News Oct 23, 2014
Foundation Medicine, Inc. and WuXi PharmaTech Inc. have announced a collaboration to offer Foundation Medicine's comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China.
Under the terms of the collaboration, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine's FoundationOne® assay at the WuXi Genome Center in Shanghai, the first and only CLIA-certified laboratory in China. Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China. Financial terms of the collaboration are not being disclosed.
"China is poised to become the second-largest pharmaceutical market within the next few years," said Dr. Ge Li, chairman and chief executive officer of WuXi. "WuXi has seen rapidly increasing demand for molecular profiling services from biopharmaceutical companies as they scale up R&D operations and early development activities in the region. We are pleased to partner with Foundation Medicine, the recognized global leader in comprehensive genomic profiling and a trusted partner of our customers, to provide best-in-class genomic testing to support targeted oncology therapeutic development in China."
"WuXi is the recognized leader in providing high-quality R&D services in China to the biopharmaceutical industry," said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. "The development and use of targeted therapies and comprehensive diagnostic tests in oncology are expected to grow significantly in China. WuXi's leadership position in China makes WuXi an ideal partner as Foundation Medicine expands its global reach to support targeted drug development and clinical entry into this rapidly growing market."
Foundation Medicine is working with more than 20 biopharmaceutical companies to provide comprehensive genomic profiling in more than 100 studies in 2014 alone. Publicly announced research partners include AstraZeneca, Eisai, Johnson & Johnson, Novartis, and Sanofi.
Researchers have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.READ MORE
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE